Treatment Resistant Depression Market to Surpass US$ 1,545.6 Mn by 2030 | Aurobindo Pharma Ltd, AbbVie Inc, AstraZeneca, Lupin, H. Lundbeck A/S, Eli Lilly and Company.

Overview:

Depression is a significant mental condition which is characterized by loss of interest and a sense of sadness. This affects the patient’s behavior, feelings, thinking and can also cause several physical and mental difficulties. Clinical depression is the other name for depression. This condition can make it difficult for patients to perform simple daily tasks. Antidepressants can help in relieving from symptoms of depression, reduce anxiety disorders, seasonal affective disorder and social anxiety disorder.

Global treatment resistant depression market is forecast to be valued at US$ 1,180.0 Million in 2022, during the forecast period.

Click Here to Get a Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/5196

Drivers:

Major players are focusing on launching new products and receiving approvals for their treatment resistant depression drugs which is estimated to propel growth of the global treatment resistant depression market during the forecast period. For instance, Denovo Biopharma LLC, declared that they have gained authorization for their new investigational drug DB104 (liafensine), in January 2022, which can be used for treatment-resistant depression. The company can now initiate Phase 2b clinical trial for assessing the efficacy and safety of liafensine.

Rising incidences of depression is anticipated to boost growth of the global treatment resistant depression market during the forecast period. For instance, National Institute of Mental Health published their data in January 2022, stating that in 2020, in the U.S. almost 21.0 million adult individuals suffered from at least one depressive episode. This accounted for 8.4% of adults in the 2020, in the U.S.

Impact of COVID-19:

The pandemic disrupted healthcare facilities globally. For instance, the European Pharmaceutical Review journal published an article in November 2020, which mentioned that coronavirus has resulted in huge challenges such as rising costs of manufacturing, and shortage of drugs around the world. Furthermore, they also mentioned that the pandemic also resulted in delay in transportation, stockpiling drugs and many others. Digital network platforms have been designed for working with many pharmaceuticals which ensures that drugs are delivered to patients around the world on time.

Restraints:

Increasing costs of drugs used during the treatment resistant depression medication is estimated to hamper growth of the global treatment resistant depression market during the forecast period. For instance, in March 2019, Johnson & Johnson declared that their nasal spray used for treating depression, is called as Spravato, will cost US$ 885 for 84 mg and US$ 590 for 56 mg dose.

Unfavorable drug reactions is estimated to hamper growth of the global treatment resistant depression market over the forecast period. Anxiety, dizziness, lethargy, hypoesthesia, sedation, increasing blood pressure, nausea, vertigo, intoxication, hypoesthesia and vomiting are some of the most common reactions witnessed in patients.

Regional Analysis:

North America, among regions is estimated to witness robust growth in the global treatment resistant depression market over the forecast period, due to increasing adoption of growth strategies like partnerships by major players. For instance, Novamind, declared that Merck & Co has selected Cedar Clinical Research, their subsidiary as a key research sites for conducting a clinical trial in treatment-resistant depression, in March 2021. This phase II study will be assessing the safety and efficacy of a new drug by Merck, MK-1942 which will be used for treatment-resistant depression.

Market Taxonomy:

By Drug Type :

• Antidepressants
  • Selective Serotonin Reuptake Inhibitors
  • Serotonin-norepinephrine Reuptake Inhibitors
  • Others
• Atypical agents
• Others

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• Europe
• Asia Pacific
• Middle East
• Africa

Key Players:

Key players active in the global treatment resistant depression market are Aurobindo Pharma Ltd, AbbVie Inc., AstraZeneca, Lupin, H. Lundbeck A/S, Eli Lilly and Company, Otsuka Holdings Co., Ltd., GlaxoSmithKline Plc., Viatris Inc., Pfizer Inc., Merck & Co., Inc., Bausch Health Companies Inc., Johnson & Johnson, Sanofi and Mallinckrodt.

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/5196

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Treatment Resistant Depression Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Treatment Resistant Depression Industry Impact

Chapter 2 Global Treatment Resistant Depression Competition by Types, Applications, and Top Regions and Countries
2.1 Global Treatment Resistant Depression (Volume and Value) by Type
2.3 Global Treatment Resistant Depression (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Treatment Resistant Depression Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Treatment Resistant Depression Market Analysis
Chapter 6 East Asia Treatment Resistant Depression Market Analysis
Chapter 7 Europe Treatment Resistant Depression Market Analysis
Chapter 8 South Asia Treatment Resistant Depression Market Analysis
Chapter 9 Southeast Asia Treatment Resistant Depression Market Analysis
Chapter 10 Middle East Treatment Resistant Depression Market Analysis
Chapter 11 Africa Treatment Resistant Depression Market Analysis
Chapter 12 Oceania Treatment Resistant Depression Market Analysis
Chapter 13 South America Treatment Resistant Depression Market Analysis
Chapter 14 Company Profiles and Key Figures in Treatment Resistant Depression Business
Chapter 15 Global Treatment Resistant Depression Market Forecast (2022-2028)
Chapter 16 Conclusions
Research Methodology